Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
CAMBRIDGE, Mass., April 27, 2018 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will webcast presentations from its Investor Day, including first quarter financial results, on Friday, May 4, 2018 at 8:00 a.m. ET in New York.
Presentations will be given by members of Agios' leadership team and external speakers including:
- David Schenkein, M.D., Chief Executive Officer
- Scott Biller, Ph.D., Chief Scientific Officer
- Chris Bowden, M.D., Chief Medical Officer
- Andrew Hirsch, Chief Financial Officer and Head of Corporate Development
- Steve Hoerter, Chief Commercial Officer
- Darrin Miles, Vice President, IDH Program Management
- Susan Pandya, M.D., Senior Medical Director, Clinical Development
- Kevin Marks, Ph.D., Senior Director, Head of Cancer Biology
- Maeve Lowery, M.B., B.Ch., B.A.O, Trinity College Dublin
A live webcast of the presentations can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The presentations are scheduled to begin at 8:00 a.m. ET and conclude at 12:00 p.m. ET. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Investors:
Renee Leck, 617-649-8299
Senior Manager, Investor Relations
[email protected]
Media:
Holly Manning, 617-844-6630
Associate Director, Corporate Communications
[email protected]
